Functional Dyspepsia
On this page
Direct answer
Epigastric pain or burning, bothersome postprandial fullness or early satiation — for at least three months with onset six months earlier, with no structural lesion on evaluation — defines functional dyspepsia, which Rome IV splits into postprandial distress syndrome (fullness after meals, early satiation) and epigastric pain syndrome (pain or burning not necessarily meal-related). After excluding alarm features (weight loss, dysphagia, recurrent vomiting, gastrointestinal bleeding, anaemia, age over 60 at onset), the pathway is Helicobacter pylori test-and-treat (stool antigen or urea breath test, never serology) and a proton pump inhibitor for four to eight weeks. Persistent symptoms move to prokinetics such as domperidone or itopride, then low-dose amitriptyline or mirtazapine; eradication of H. pylori cures a small but real minority, and the rest are managed, not cured.
What you must remember
- Rome IV subtypes to name: postprandial distress syndrome — bothersome fullness after ordinary meals or early satiation preventing a normal finish, at least three days a week; epigastric pain syndrome — pain or burning at least one day a week, intermittent, not necessarily related to meals.
- Alarm features mandating endoscopy: age over 55-60 at presentation, weight loss, dysphagia, persistent vomiting, haematemesis or melaena, iron-deficiency anaemia, palpable mass, and a family history of upper gastrointestinal cancer — Indian practice leans younger for endoscopy because gastric cancer presents earlier.
- Test for H. pylori correctly: stool antigen or urea breath test (off PPI for two weeks, off antibiotics and bismuth for four); serology detects past exposure and cannot diagnose active infection — a classic wrong option.
- The PPI course: standard dose for four to eight weeks, then stop — continuing indefinitely without reassessment is poor practice, and on-demand therapy is reasonable for episodic epigastric pain syndrome.
- Prokinetic shelf: domperidone 10-20 mg before meals (QT caution, avoid combining with CYP3A4 inhibitors), itopride 50 mg thrice daily — widely prescribed in India, dopamine D2 antagonist with acetylcholinesterase inhibition — and mosapride; best evidence is for postprandial distress syndrome.
- Neuromodulators for refractory symptoms: amitriptyline 10-25 mg at night or mirtazapine 15 mg (particularly when weight loss from early satiation is the problem); buspirone improves fundic accommodation and is a mechanistic answer for postprandial fullness.
- H. pylori eradication arithmetic: eradication produces symptomatic relief in roughly one in 12-15 treated patients beyond placebo (number needed to treat often quoted near 12), so most dyspepsia persists even after successful cure.
- Diet and lifestyle triggers: fat-heavy meals, large volumes, coffee, alcohol, NSAIDs and tobacco aggravate; corrected before declaring the patient treatment-refractory.
Test-and-treat, then step up
A 32-year-old software engineer reports a year of postprandial fullness, early satiation and epigastric burning, losing 3 kg because meals have shrunk; there is no dysphagia, no vomiting, no bleeding, and examination is normal. Being under 60 without alarm features, he takes the test-and-treat path: H. pylori stool antigen is positive, so quadruple therapy per local resistance — a PPI, clarithromycin and amoxicillin where resistance is low, or bismuth-based quadruple therapy where it is high (India's clarithromycin resistance makes bismuth quadruple therapy a common first choice) — for 14 days, with eradication confirmed by stool antigen or breath test at least four weeks after finishing the PPI. Symptoms ease modestly but fullness persists, so the ladder continues: PPI for eight weeks (partial benefit for the burning), then itopride 50 mg thrice daily before meals for the fullness; at twelve weeks residual early satiation is treated with mirtazapine 15 mg at night, which restores appetite and sleep.
Had he been 62 with the identical pain and 6 kg lost, the very first step would instead be upper gastrointestinal endoscopy — the age-and-alarm gate overrides every symptomatic pathway.
Where students slip
The recurring mistake is treating H. pylori serology as a diagnostic test — IgG persists after eradication, so a positive serology in a treated patient means nothing; the exam answer is stool antigen or breath test confirming active infection. The second slip is mislabelling all epigastric pain as dyspepsia without asking the meal relationship that separates the Rome IV subtypes — postprandial distress (fullness, satiation, prokinetics) versus epigastric pain (burning, PPI) — because the subtype steers therapy. Third, candidates forget that heartburn-dominant disease is not dyspepsia: if reflux symptoms dominate, the patient belongs to the GERD pathway. Finally, Indian exams embed the H. pylori resistance detail — high clarithromycin resistance pushes first-line treatment toward bismuth-based quadruple therapy and 14-day courses, a national-management nuance that separates prepared candidates from the rest.
Frequently asked questions
What are the Rome IV subtypes of functional dyspepsia?
Postprandial distress syndrome (bothersome fullness after meals or early satiation, three or more days a week) and epigastric pain syndrome (intermittent pain or burning at least one day a week), both for three months with six-month onset and no structural cause.
Which tests diagnose active H. pylori infection?
Urea breath test and stool antigen test — both requiring a PPI-free interval of two weeks — while serology only reflects past exposure and cannot confirm active infection.
When does dyspepsia go straight to endoscopy?
With alarm features — age over about 55-60 at onset, weight loss, dysphagia, recurrent vomiting, bleeding, anaemia or a mass — or persistent symptoms despite test-and-treat and a PPI course.
Which drugs help postprandial distress syndrome specifically?
Prokinetics such as domperidone or itopride before meals, buspirone to improve fundic accommodation, and mirtazapine or low-dose amitriptyline for refractory early satiation and associated weight loss.
Does H. pylori eradication cure functional dyspepsia?
It cures a small minority — roughly one in 12-15 patients gains symptom relief beyond placebo — so eradication is worthwhile but most patients need symptomatic management afterwards.